Atsuhiro Sugidachi

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Lars Wallentin, Christoph Varenhorst, Stefan James et al. · European Heart Journal · 2007 · 455 citations · Full text

Medicine, Cardiology, Pharmacology +17

The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa et al. · British Journal of Pharmacology · 2000 · 235 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara et al. · Journal of Thrombosis and Haemostasis · 2007 · 218 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

David Erlinge, Christoph Varenhorst, Oscar Ö. Braun et al. · Journal of the American College of Cardiology · 2008 · 216 citations

Medicine, Endocrinology, Pharmacology +17

Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

Dominick J. Angiolillo, Joseph A. Jakubowski, José Luis Ferreiro et al. · Journal of the American College of Cardiology · 2014 · 180 citations

Medicine, Cardiology, Pharmacology +17